RFPi aspires to become a leader in real-time, non-invasive medical imaging. A mid-stage company, RFPi is pioneering breakthrough medical imaging technologies to improve surgical outcomes; reduce health-care costs, repeat surgeries and hospital readmissions; and enhance patient care. RFPi’s patented and copyrighted intellectual properties propelled the creation of its iCertainty platform, which provides immediate visualization and quantification of blood flow and perfusion without injections (dyes), radiation or the need for direct patient contact.
For more information, contact Jeff Basham.
Chairman and Angel Funder
Phil Hodges is a successful entrepreneur with more than 30 years of executive leadership experience in health sciences.
A founder of Metrics Inc., Mr. Hodges oversaw the company’s growth from a startup contract analytical lab with just four employees into a 300-person pharmaceutical development, formulation, manufacturing and analytical support services organization owning a portfolio of niche generic products. In 2012, Mr. Hodges led negotiations for his company’s successful acqusition by Mayne Pharma Group Limited for $120 million. He is one of Mayne Pharma’s largest shareholders and serves on the company’s board of directors.
Upon leaving the day-to-day management of Metrics, Mr. Hodges created a venture capital fund to support early-stage medical product development and is an angel funder of RFPi.
Serial startup entrepreneur Jeff Basham has years of experience advancing health-care innovations from concept to fruitful acquisition or commercialization. He was founding CEO of a group of companies that became Closure Medical, which developed the first successful synthetic wound closure glue and eventually was sold to Johnson & Johnson for $500 million.
Mr. Basham also directed the turnaround of Entegrion, a hemostatic-focused startup for which he raised new capital by organizing and closing on more than $50 million worth of U.S. Department of Defense development funds.
Most recently, Mr. Basham was vice president of business development at Metrics Inc., a contract pharmaceutical development and manufacturing organization. Led by Mr. Basham’s business development efforts, the company experienced double-digit revenue growth annually.
Peter Geiger spent seven years serving as chief financial officer at DSM Pharmaceuticals, a contract pharmaceutical manufacturing producing $2 billion worth of consumer products annually.
Mr. Geiger brings to RFPi significant financial leadership in health services startups. As managing general partner of Geiger Investments Ltd., Mr. Geiger applies his expertise in company valuation to help generate above-market returns for partners.
Holding an undergraduate degree in behavioral neuroscience from Lehigh University, Mr. Geiger graduated with honors from the Wharton School of Business at the University of Pennsylvania with an MBA in finance and strategic management.
Chief Medical Officer
Internationally renowned cardiovascular surgeon Dr. Bruce Ferguson is one of the creators of RFPi’s proprietary and innovative real-time imaging technology. And as Chief Medical Officer at RFPi, he will be instrumental in guiding the development of applications and intellectual property moving forward.
A tenured professor in the Department of Cardiovascular Sciences at East Carolina University’s Brody School of Medicine, Dr. Ferguson served as the department’s inaugural chairman from 2007-2012. He brings to RFPi experience with extramural funding at Washington University in St. Louis, Louisiana State University in New Orleans, and the ECU Brody School of Medicine.
Dr. Ferguson is a highly regarded leader in his field of expertise. He currently serves as the international surgical lead on the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), the purpose of which is to determine the best management strategy for higher-risk patients with stable ischemic heart disease, a study sponsored by the National Heart, Blood and Lung Institute (NHLBI), part of the National Institutes of Health. He also served as principle investigator on ECU’s component of a joint Duke University/East Carolina Heart Institute clinical site of the NHLBI Cardiac Surgical Network from 2007-2013.
An early adopter of data-driven and quality-outcomes medicine who has extensive experience in clinical databases, Dr. Ferguson was the first chairman of the Society of Thoracic Surgeons’ Council on Quality, Research and Patient Safety, which manages the organization’s national databases. He was a member of the Institute of Medicine group that recently authored “Best Care at Lower Cost: The Path to Continuously Learning Health Care in America.”
By recruiting and engaging a multi-disciplinary team representing optical physics, mechanical engineering, electrical engineering, biomechanical engineering and cardiovascular physiology, Dr. Ferguson has spearheaded development of RFPi’s technology within the past two years and overseen testing of working prototypes at RFPI’s optical imaging laboratory in the Warren Life Sciences Building at ECU’s Brody School of Medicine.
A graduate of the Washington University School of Medicine, Dr. Ferguson completed his residency and fellowship at Duke University Medical Center. He is certified by both the American Board of Surgery and the American Board of Thoracic Surgery.
Chief Science and Technical Officer
Highly regarded optical physicist Dr. Cheng Chen has collaborated with Dr. Bruce Ferguson on RFPI’s medical-imaging technology since 2008. With expertise in software and hardware development, Dr. Chen proved critical for the initial patenting of the technology, and his vision will lead to further application and intellectual property product expansions.
Dr. Chen is a research instructor in the Department of Cardiovascular Sciences at East Carolina Heart Institute and the Brody School of Medicine at ECU. He is a member of “National Academy of inventors” and has been nominated and awarded in multiple scientific and clinical meeting and congress.
Drs. Chen and Ferguson were the first to recognize the enormous clinical potential for real-time analysis of blood flow and perfusion. Relying upon Dr. Ferguson’s clinical experience and expertise, Dr. Chen developed the software for the new NIRF Complex Angiography and Perfusion Analysis (CAPA) platform, and maintains the ECHI clinical imaging database of 1,000-plus patients operated upon and imaged with NIRF by Drs. Ferguson and Chen.
Dr. Chen earned his doctorate in optical physics from East Carolina University under the supervision of Dr. Xin-hua Hu. Together, they have co-filed one patent on optical imaging of turbid biological medium (e.g., blood, skin and other tissue/organs) and published numerous papers in peer reviewed scientific journal on this topic, and Dr. Hu has additional patents on the mathematical development of flow dynamic modeling and its application in flow cytometry. Drs. Ferguson, Chen and Hu are co-inventors of the Multi-Spectral Physiologic Visualization imaging technology used in this project. The IP portfolio currently has two Patents, with over ten additional applications under review nationally and internationally.